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Background: The risk of hemochromatosis-related morbidity among HFE simple 
heterozygotes for either C282Y or H63D substitutions in the HFE protein was assessed in a 
prospective population-based cohort study. 
	  
Methods: HFE genotypes were measured in 31,192 persons of northern European descent 
between the ages of 40 and 69 years who participated in the Melbourne Collaborative 
Cohort Study and were followed for an average of 12 years. In a random sample of 1438 
subjects stratified according to HFE genotype and selected for invitation to participate, the 
following data were obtained: two sets of biochemical iron indices performed 12 years apart 
and, at follow-up only, the presence/absence of six disease features associated with 
hereditary hemochromatosis. Summary measures for 257 (139 female) C282Y and 123 (74 
female) H63D simple heterozygotes were compared with 330 (181 female) controls with 
neither HFE mutation.  
 
Results: At baseline, men, pre-menopausal women and post-menopausal women had, on 
average, clinically normal transferrin saturation (TS) levels irrespective of HFE simple 
heterozygosity. Mean TS (95% confidence interval) and prevalence of TS > 55% was 
35.14% (33.25,37.04) and 3/112(3%); 33.03% (29.9,36.15) and 0/39(0%); and 29.67% 
(27.93,31.4) and 3/135(2%) for C282Y, H63D, and wild-type male participants, respectively. 
At follow-up, mean TS levels remained similar to baseline levels for men, pre- and post- 
menopausal women who were simple heterozygotes for either C282Y or H63D. No HFE 
C282Y or H63D simple heterozygotes had documented iron overload (based on hepatic iron 
measures or serum ferritin greater than 1000µg/L at baseline with documented therapeutic 
venesection). After stratifying by sex, the disease features of both C282Y and H63D simple 
heterozygotes were similar to those of HFE wild-type participants. 
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Conclusion: No documented iron overload was observed for HFE simple heterozygotes for 
either C282Y or H63D, and morbidity for both HFE simple heterozygote groups was similar 
to that of the HFE wild-type participants. 
 
Introduction 
Hereditary hemochromatosis (HH) is a genetic predisposition to iron overload which, if not 
prevented or treated, increases the risk of diseases including liver cirrhosis, arthritis, fatigue 
and diabetes [1]. Two mutations in the HFE gene, C282Y and H63D, are responsible for the 
majority of clinical cases of iron overload [2]. In particular two HFE genotypes, C282Y 
homozygosity and C282Y/H63D compound heterozygosity, confer an increased risk of iron 
overload-related disease [2, 3]. Both of these HFE genotype groups have been studied 
extensively in both population and clinical studies, and their epidemiological profile is well 
established [4, 5] add Gurrin et al. (Hepatology 2009).  
 
Two HFE genotype groups that have received less attention are the simple heterozygotes 
for either the C282Y or the H63D mutation. In populations of northern European descent, 
H63D simple heterozygosity is more prevalent (23.6% to 31.1%) [6-8] than C282Y simple 
heterozygosity (8.6% to 11.9%) [5-7, 9]. Despite these high prevalences the population risk 
of HFE C282Y simple heterozygotes and HFE H63D heterozygotes developing HH-
associated clinical signs and symptoms or iron overload-related disease has not been widely 
examined. If this risk is increased compared to that of the general community then it would 
have an immediate implication for population genetic screening for HFE mutations, since 
such screening would potentially label a large proportion of the population as both being at 
increased risk of disease, and as carriers of a disease causing mutation. 
 
Large cross-sectional population-based studies show that, on average, serum ferritin 
concentration (SF) and transferrin saturation (TS) levels for C282Y simple heterozygotes are 
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within their respective clinically normal reference ranges, but tend to be higher compared to 
that those with a lack of a detectable C282Y or H63D mutation, designated as HFE wild-
type, for both sexes [5, 6, 9, 10]. Similarly, mean SF and TS levels for H63D simple 
heterozygotes are within their respective clinically normal ranges, and comparable to HFE 
wild-types for both males and females [6]. Male C282Y simple heterozygotes have been 
reported to have 0.81-fold decrease (95%CI: 0.71-0.94) in the odds of diabetes compared to 
HFE wild-types [6] although the prevalence of diabetes in this study (11.5%) and our own 
cohort (2%) is low [5, 11]. An Australian study found no evidence that the presence of the 
H63D mutation resulted in an increased risk of clinically significant iron overload [8]. In the 
work-place setting the prevalence of self-reported tiredness, abdominal pain, joint pain and 
previous diagnosis of diabetes, arthritis and liver disease in simple C282Y heterozygotes 
was comparable to the prevalence of these symptoms/diseases in HFE wild-type individuals 
[12]. 
 
These previous studies [4, 8-10] experience a number of shortcomings. They did not record 
and, therefore, could not stratify by women’s menopausal status, and none have measured 
iron indices in the same participants at two or more time points.  Participants were examined 
by medical practitioners who were not blinded to their HFE genotype status. In some studies, 
HFE-associated signs, symptoms and features of disease were not examined; only iron 
indices were assessed [9, 10]. Findings from the study in the work-place setting may not be 
generalizable to the wider population due to the possibility of selection bias [12].  
 
The “HealthIron” study, results of which we present in this paper, does not suffer from the 
deficiencies outlined in the previous paragraph. We examined clinical and epidemiological 
data from HFE C282Y and H63D simple heterozygotes and wild-type individuals who were 
followed over a 12-year period and at ages when those at risk of iron overload would have 
been expected to develop iron overload-related disease (from 40-69 years at baseline to 54-
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83 years at follow-up). We describe the natural history of serum iron indices and iron 




The Melbourne Collaborative Cohort Study (MCCS) 
Between 1990 and 1994, the Melbourne Collaborative Cohort Study (MCCS) recruited 
41,514 people (24,469 females) aged between 27 and 75 years (99% were aged 40 to 69 
years) [13]. At baseline, participants attended a study centre where they completed a 
questionnaire about dietary and lifestyle factors, underwent a physical examination and 
provided a blood sample. 
 
The HealthIron Study 
Beginning in 2004, 31,192 MCCS participants of northern European descent (born in 
Australia, the United Kingdom, Ireland or New Zealand) were genotyped for the C282Y HFE 
mutation using stored baseline blood samples. Participants of southern European descent 
(n=10,336) were excluded due to the low prevalence of HFE mutations. Those with one copy 
of the C282Y mutation were then genotyped for H63D to determine whether they were 
simple (one copy of the C282Y mutation) or compound heterozygotes (one copy of each of 
the C282Y and H63D mutations). 
 
All participants homozygous for the C282Y mutation (n=203) plus a random sample stratified 
by the other three HFE genotypes (C282Y/H63D compound heterozygote, C282Y simple 
heterozygote, no C282Y mutation) that were selected for invitation to attend follow-up clinics 
between 2004 and 2006 as part of the HealthIron study. H63D simple heterozygotes were 
identified by genotyping of those with no C282Y mutation who attended the follow-up clinic. 
Of the 1,438 people invited to participate in the HealthIron study, 107 were deceased and 
277 were lost to follow-up, leaving 1,054 who participated. The overall participation by those 
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invited was 73.3 per cent (79.2 per cent excluding those already deceased) with no 
significant variation in participation when stratified by genotype (data not shown). 
 
At baseline, participants had a fasting blood sample taken and completed questionnaires 
that included information about diet, alcohol intake and medical history. Follow-up clinics 
were held between 2004 and 2006. As part of the study, participants completed a computer-
assisted personal interview that included information about medical history, blood donation, 
had a fasting blood sample taken for iron studies and liver enzymes, were examined by a 
medical practitioner blinded to genotype and had a cheekbrush swab taken to confirm the 
original HFE genotype from their baseline blood sample. 
 
All participants gave written informed consent to participate in both the MCCS and the 
HealthIron sub-study. Both protocols were approved by the Cancer Council Victoria’s Human 
Research Ethics Committee. 
 
Definitions of biochemical / clinical exposures and outcomes 
Iron indices 
Elevated SF was defined for males and post-menopausal females as >300 µg/L and for pre-
menopausal females >200 µg/L. Elevated transferrin saturation (TS) was defined for males 
as >55% and for females >45%. When examining the prevalence of disease by elevated iron 
indices, SF was considered to be elevated if the SF value exceeded the specified threshold 
on at least one occasion. We defined normal SF as having values below these thresholds at 
both baseline and follow-up.  
 
Disease features and iron overload-related disease (IORD) 
We investigated the prevalence of six disease features associated with hereditary 
hemochromatosis (HH): Abnormal (i.e. presence of bony spur, effusion or tenderness) 
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second and/or third metacarpophalangeal (MCP) joints on either hand (MCP 2/3), use of 
arthritis medication, self reported fatigue, raised aspartate aminotransferase or raised 
alanine aminotransferase levels (raised AST or raised ALT), self reported history of liver 
disease and/or hepatomegaly. With the exception of the use of arthritis medication, which 
was assessed at baseline and follow-up, all disease features were measured at follow-up 
alone.  
 
Iron overload-related disease (IORD) was defined as the presence of one of the following 
five features: Hepatocellular carcinoma, liver cirrhosis or fibrosis, abnormal 2nd/3rd MCP, 
raised aminotransferases or physician-diagnosed HH due to symptoms in the context of 
either provisional or documented iron overload (see footnotes to Table 6 for definition) [5]. 
 
Menopausal status and blood donation history  
Menopausal status for women was measured at baseline and classified as pre-menopausal 
or post-menopausal. Blood donation history was classified at baseline as never, former 
(ceased before baseline) or current (still donating at baseline). 
 
Statistical analysis of biochemical and clinical outcomes  
The Mann-Whitney U test was used to detect differences in both location and spread of age, 
BMI and alcohol intake between groups. For all analyses SF levels were natural log 
transformed. Comparisons of mean log SF and TS measurements between groups at either 
baseline or follow-up were made using the two sample t-test and comparisons within groups 
comparing baseline and follow-up were made using the paired t-test. Two-sided p-values are 
presented. No correction for multiple testing was made since we present a relatively small 




The prevalence of elevated iron indices and disease features was estimated as the 
observed proportions at a single time point, and comparisons between groups were made 
using Pearson’s chi-squared test. If cell counts were less than 5 then Fisher’s exact test was 
performed. Some subjects did not participate in all components and as a result did not 
contribute data to the prevalence calculation for every disease feature.  
   
We examined the influence of co-morbid factors on liver enzymes by conducting separate 
analyses, excluding participants with a body mass index (BMI) greater than 30 kg/m2 or 
alcohol intake greater than 60g/day for men and greater than 40g/day for women when 
calculating the prevalence of raised AST/ALT. Increased BMI and alcohol intake are 
common causes of raised iron indices and abnormal serum transaminase levels. 
 
Participants who were diagnosed and treated for HH and those with any SF>1000 µg/L were 
included in the analysis. Their inclusion avoids a downward bias of the estimated prevalence 
of disease features at follow-up due to the exclusion of cases with clinical symptoms. 
 
Results 
HFE genotyping was successful for 29,676 of 31,192 (95%) subjects of whom 3295 (11.1%) 
were C282Y simple heterozygotes. There were 337 C282Y simple heterozygotes and 621 
participants with no copies of the C282Y mutation who were selected for invitation to the 
HealthIron study. Of these, 257 C282Y simple heterozygotes and 469 without the C282Y 
mutation attended the follow-up clinic (response fractions of 76.3% and 75.5% respectively). 
Subsequent genotyping revealed that of those without the C282Y mutation attending the 
clinic, 123 (74 women) were simple heterozygotes for H63D and 330 (181 women) were 
wild-type for HFE. The remaining 16 participants (10 women) attending the clinic were 
homozygous for the H63D mutation and were excluded from further consideration in this 
study. Close to or more than half of all women in each of the three HFE genotype groups 
Page 10 
were post-menopausal at baseline (63/139 (45%) C282Y simple heterozygotes, 44/74 (59%) 
H36D simple heterozygotes and 110/181 (61%) HFE wild-types). 
 
For men and women, there was little difference in the median and IQR of age, BMI and daily 
alcohol intake for C282Y and H63D simple heterozygotes compared to HFE wild-types 
(Table 1). The Mann-Whitney U test identified a statistically significant difference in the 
median and spread of the distribution of daily alcohol intake for female C282Y simple 
heterozygotes (median: 4.3 g/day; IQR: 0-16.5) compared to HFE wild-types (median: 1.0 
g/day; IQR: 0-8.6), and the distribution of BMI for female C282Y simple heterozygotes 
(median: 24.5 g/day; IQR: 22.1-27.1) compared to HFE wild-types (median: 25.3 g/day; IQR: 
23.2-28.5), although the median and spread of BMI appeared to be similar for both of the 
latter genotype groups. These differences were, however, small in magnitude and therefore 
not clinically relevant. The blood donation history of HFE simple heterozygotes for either 
C282Y or H63D was comparable to wild-types for men, pre-menopausal women and post-
menopausal women (Table 2).  
 
Iron indices 
C282Y and H63D simple heterozygotes had, on average, normal serum ferritin  and 
transferrin saturation (TS) levels at baseline irrespective of sex and menopausal status 
(Table 3). At follow-up, geometric mean SF levels and mean TS levels remained within the 
normal range and similar to baseline levels for men and post-menopausal women regardless 
of whether they had the C282Y or H63D substitution in the HFE protein (Table 4). For pre-
menopausal women, the onset of menopause increased the geometric mean SF levels of 
C282Y simple heterozygotes (Baseline: 36.3µg/L (95% CI: 28.3,46.5); Follow-up: 87.1µg/L 
(95% CI: 69.3,109.5)) and H63D simple heterozygotes (Baseline: 57.34µg/L (95% CI: 
36.14,90.97); Follow-up: 80.4µg/L (95% CI: 51.45,125.64)). For both C282Y and H63D 
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simple heterozygotes, the prevalence of elevated SF or TS was comparable to HFE wild-
types at both time points and particularly low for women (Table 5). 
 
Two C282Y simple heterozygotes (one man and one woman), two H63D simple 
heterozygotes (one man and one woman) previously reported having been diagnosed with 
haemochromatosis, but none reported being treated with therapeutic venesection during the 
study period. None of them had elevated transferrin saturation and three had BMI greater 
than 30 kg/m2, so although all four had elevated SF at either baseline or follow-up, this is 
likely to be an incidental finding that was incorrectly diagnosed by their primary care 
physicians as being consistent with hereditary haemochromatosis. Also incidental is the fact 
that all four gave different reasons for diagnosis (routine blood examination, genetic test, 
presence of symptoms, and “other/don’t know”). Two male C282Y simple heterozygotes and 
one male HFE wild-type had baseline SF>1000 µg/L and baseline TS<55%. At follow-up, 
one male H63D simple heterozygote had SF>1000 µg/L and TS<55% and one male HFE 
wild-type had SF>1000 µg/L and TS>55%. All had BMI greater than 30 kg/m2, with the 
exception of the male H63D simple heterozygote, whose BMI was 25.8 kg/m2 and they were 
abstinent from alcohol. We note in passing that HFE C282Y homozygotes with SF>1000 
µg/L rarely have TS < 55% (Allen et al. (2008), Gurrin et al. (Gastroenterology 2008)) 
whereas of the five participants in the current study with SF>1000 µg/L only one had TS > 
55%, further suggesting that elevated serum ferritin is attributable to co-morbid factors rather 
than iron overload. What about ferroportin diseaseIn such individuals if you measure hepatic 
iron concentration there is no increase above general population levels – for reference see 
our Clin Gastroenterol Hepatol paper 2009 and our 2013 paper that shows the reference 
range for ferritin in Australian probably needs a significant upward adjustment JO??? 
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Prevalence of disease features 
The estimated prevalence of the six disease features for each sex and HFE genotype group 
are given in Table 6. After stratifying by sex, the prevalence of disease features of both 
C282Y and H63D simple heterozygotes was similar to wild-types, with the exception of a 
lower prevalence of raised AST or ALT for male C282Y simple heterozygotes (5%) 
compared to wild-types (14%). After individuals who were obese (BMI>30 kg/m2) or who had 
high alcohol intake (>60 g/day for men or >40 g/day for women) were excluded, abnormal 
liver enzymes were significantly less prevalent for male C282Y simple heterozygotes (3/93 
(3.2%)) relative to wild-types (15/105 (14%)). For male and female C282Y and H63D simple 
heterozygotes, the observed prevalence of disease was similar for those with elevated SF 
and those with normal SF (Table 7). Excluding those participants who were obese or with a 
heavy alcohol intake did not alter this finding.  The small absolute numbers suggest that this 
is not clinically relevant. 
 
Table 8 presents the prevalence of iron overload-related disease for C282Y and H63D 
simple heterozygotes. No male and no female C282Y or H63D simple heterozygotes had 
documented iron overload-related disease. Two male C282Y simple heterozygotes, one 
female C282Y simple heterozygote pre-menopausal at baseline and one male H63D simple 
heterozygote fitted the criteria of provisional iron overload (as defined in [5] and at the 
bottom of Table 6), but had none of the six disease features associated with HH. Two male 
HFE wild-types fitted the criteria of provisional iron overload, only one of whom reported 
experiencing disease features associated with HH; arthritis medication and fatigue.  
 
Discussion 
This study is the first to describe the natural history of serum iron indices, and to determine 
whether HH-associated features and iron overload-related disease develop in HFE C282Y 
and H63D simple heterozygotes. Iron indices remained stable, and, on average, within their 
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clinically normal ranges in middle age for C282Y and H63D simple heterozygotes, so these 
individuals are unlikely to be candidates for therapeutic venesection for iron overload. 
Menopause resulted in increased mean SF for pre-menopausal female C282Y and H63D 
simple heterozygotes and wild-type participants, but the iron indices, on average, remained 
within their normal ranges. No documented iron overload was observed for HFE simple 
heterozygotes for either C282Y or H63D, and iron overload related disease morbidity for 
both HFE simple heterozygote groups was similar to HFE wild-types.  
 
We note that the thresholds used to define elevated SF and elevated TS differ between 
cross-sectional population studies, and some thresholds are sex dependent while others are 
not [6, 8-10]. Our results on the prevalence of elevated iron indices are in line with those 
from other studies so it is unlikely that our conclusions are sensitive to the choice of 
threshold for the clinically normal range of iron indices such as TS and SF. See my earlier 
comment on our recent study on what should be the appropriate reference range for ferritin 
Lyle 
 
In the introduction we outlined the advantages of the longitudinal design over cross-sectional 
clinical studies. There is only one other prospectively-recruited, population-based study that 
focussed specifically on hereditary haemochromatosis. Our findings are consistent with the 
results of that study, but extend their findings by reporting on serial iron indices and clinical 
examination at follow-up more than a decade after recruitment. Nevertheless, our study does 
have some weaknesses. The majority of participants were recruited in middle age so our 
conclusions do not necessarily apply to younger age groups. Clinical examination for 
haemochromatosis-associated features was not conducted at baseline, so we relied on self-
reported information from questionnaires and interviews. Data on magnetic resonance 
imaging or liver biopsy to quantify hepatic iron content were not part of the protocol for 
clinical examination at follow-up, and was only performed when clinically indicated by the 
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participants’ physician independently of their involvement in this study. However, in a 
separate study we have shown that such subjects do not have iron loading above general 
population levels (Olynyk et al Clin Gastroenterol Hepatol 2009). For participants who had 
therapeutic venesection or who engaged in voluntary (or altruistic) blood donation, 
quantitative phlebotomy was self-reported although, where possible, records were linked to 
the Australian Red Cross Blood Service to establish the validity of the self-reported number 
of episodes of blood removal [14]. 
 
In conclusion, HFE simple heterozygotes for either C282Y or H63D are at low risk of 
developing iron overload in middle age, and rarely exhibit any of the symptoms of HH. We 
found no evidence that HFE simple heterozygotes would benefit from more frequent medical 




Table 1: Participant information at baseline: age, BMI and alcohol intake stratified by genotype 
and sex. 
 n Age (years) 
mean (sd) 
[median;IQR*] 





mean (sd)  
[median;IQR] 
p@ 
Male        
C282Y Simple 
Heterozygote 
118 53.7 (9.2) 
[52.5;45.5-61.5] 
0.67 26 (3.2) 
[25.6;23.8-27.3] 





49 54.4 (9.2) 
[52.8;46.9-63.9] 
0.91 27.4 (4.1) 
[26.7;24.6-28.9] 
0.32 15.2 (17.4) 
[12.6;.2-19.6] 
0.29 
HFE Wild-type 149 54.2 (9.1) 
[54.2;45.3-61] 
 26.8 (4.2) 
[25.9;24.3-28.3] 
 19.4 (23.3) 
[13.5;3-24.2] 
 
        
Female        
C282Y Simple 
Heterozygote 
139 52.5 (8.8) 
[50.4;44.6-59.9] 
0.29 25.1 (4.1) 
[24.5;22.1-27.1] 





74 55.2 (9.9) 
[56;44.1-64.4] 
0.25 25.3 (4) 
[24.8;22.6-27.2] 
0.15 7.6 (11.9) 
[1.7;0-12.9] 
0.90 
HFE Wild-type 181 53.7 (9.1) 
[53.5;45.2-61.7] 
 26.3 (4.6) 
[25.3;23.2-28.5] 
 7.4 (12.9) 
[1;0-8.6] 
 
*IQR – inter-quartile range 
@Two-sided p-value derived from Mann-Whitney U test comparing C282Y simple heterozygotes to HFE wild-
types, and H63D simple heterozygotes to HFE wild-types.
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Table 2: Blood donation history at baseline for simple heterozygotes and HFE wild-types by sex and, 
for women, menopause status. 
   Blood donation at baseline  
Men  n Never Former Current p# 
 C282Y Simple 
Heterozygote 
118 51(43%) 44(37%) 23(19%) 0.67 
 H63D Simple 
Heterozygote 
49 25(51%) 16(33%) 8(16%) 0.83 
 HFE Wild-type 149 71(48% 48(32%) 30(20%)  
Women       
Pre-menopausal C282Y Simple 
Heterozygote 
76 33(43%) 28(37%) 15(20%) 0.78 
 H63D Simple 
Heterozygote 
30 12(40%) 6(20%) 12(40%) 0.21 
 HFE Wild-type 71 31(44%) 23(32%) 17(24%)  
Post-menopausal C282Y Simple 
Heterozygote 
63 43(68%) 10(16%) 10(16%) 0.41 
 H63D Simple 
Heterozygote 
44 27(61%) 12(27%) 5(11%) 0.85 
 HFE Wild-type 110 67(61%) 27(25%) 16(15%)  




Table 3: Geometric mean serum ferritin (SF) and mean transferrin saturation (TS) values stratified by 
HFE genotype and sex.  Baseline SF and TS for women are stratified according to menopausal status. 
All women had become post-menopausal by follow-up. 
Baseline iron indices:       
 n Baseline SF (µg/L) @ 
geometric mean (95% CI) 
p# n Baseline TS 
(%) ** mean  (95% CI) 
p# 












0.03 39 33.03 
(29.9,36.15) 
0.07 
HFE Wild-type 133 150.81 
(128.59,176.86) 
 135 29.67 
(27.93,31.4) 
 





0.73 72 29.97 
(27.16,32.78) 
<0.01 




0.06 27 26.82 
(22.49,31.14) 
0.05 
HFE Wild-type 65 35.16 
(27.93,44.26) 
 65 22.48 
(20.27,24.69) 
 












0.31 37 28.16 
(25.58,30.75) 
0.16 
HFE Wild-type 95 83.01 
(68.3,100.9) 
 95 26.06 
(24.51,27.62) 
 
Follow-up iron indices:       
  Follow-up SF (µg/L) † 
geometric mean (95% CI) 
  Follow-up TS 
(%) * mean (95% CI) 
 












0.76 46 31.61 
(28.33,34.89) 
0.15 
HFE Wild-type 139 134.16 
(113.63,158.38) 
 140 29.14 
(27.5,30.78) 
 












0.54 66 26.83 
(24.66,29) 
0.14 
HFE Wild-type 169 80.08 
(69.29,92.55) 
 169 24.94 
(23.62,26.26) 
 
@ 46 (19 C282Y simple heterozygotes (10 males, 6 pre-menopausal females and 3 post-menopausal females), 9 H63D simple 
heterozygotes (1 male, 3 pre-menopausal females and 5 post-menopausal) and 18 HFE wild-types (8 males, 3 pre-menopausal females 
and 7 post-menopausal females)) had SF measures available at baseline but not follow-up.  
** 1 pre-menopausal female C282Y simple heterozygote, 1 pre-menopausal female H63D simple heterozygote, 1 male H63D simple 
heterozygote and 2 male HFE wild-types had a baseline TS measure but no baseline SF measure. 
† 99 (39 C282Y simple heterozygotes (17 males, 6 pre-menopausal and 16 post-menopausal females) 22 H63D simple heterozygotes (11 
males, 4 pre-menopausal females and 7 post-menopausal females) and 38 HFE wild-types (17 males, 6 pre-menopausal and 15 post-
menopausal females)) had SF measures available at follow-up but not baseline. 
* 2 female C282Y simple heterozygotes and 1 male HFE wild-type had a follow-up TS measure but no follow-up SF measure. 
|| 3 C282Y simple heterozygotes, 1 H63D simple heterozygote and 3 HFE wild-type females were pre-menopausal at follow-up. 









Table 4: Geometric mean serum ferritin (SF) and mean transferrin saturation (TS) values stratified by 
HFE genotype and sex in participants with both baseline and follow-up iron measures.   
Men n Baseline SF (µg/L) 
geometric mean (95% CI) 
Follow-up SF (µg/L) 





























































     
Men n Baseline TS (%) 
mean (95% CI) 
Follow-up TS (%) 





























































† Women classified as pre-menopausal at baseline. 
‡ Women classified as post-menopausal at baseline. 












Table 5: Prevalence of elevated baseline and follow-up serum ferritin (SF) and elevated baseline 
transferrin saturation (TS) for C282Y simple heterozygotes, H63D simple heterozygotes and HFE wild-
types. 





Men      
 C282Y Simple 
Heterozygote 
33/112(29%) 0.41 33/107(31%) 0.07 
 H63D Simple 
Heterozygote 
14/38(37%) 0.14 6/46(13%) 0.24 
 HFE Wild-type 33/133(25%)  29/139(21%)  
Women      
 C282Y Simple 
Heterozygote 
7/122(6%) *0.22 10/125(8%) 0.25 
 H63D Simple 
Heterozygote 
7/63(11%) *0.01 6/66(9%) 0.2 
 HFE Wild-type 4/160(3%)  8/169(5%)  





Men      
 C282Y Simple 
Heterozygote 
3/112(3%) *1.00 5/107(5%) *0.24 
 H63D Simple 
Heterozygote 
0/39(0%) *1.00 2/46(4%) *0.26 
 HFE Wild-type 3/135(2%)  2/140(1%)  
Women      
 C282Y Simple 
Heterozygote 
7/123(6%) *0.02 9/127(7%) *0.08 
 H63D Simple 
Heterozygote 
2/64(3%) *0.20 1/66(2%) *1.00 
 HFE Wild-type 1/160(1%)  4/169(2%)  
@ Elevated SF for males and post-menopausal was defined as SF>300 µg/L and for pre-menopausal women was defined as SF>200 µg/L. 
Elevated TS for males was defined as TS>55% and for females>45% (irrespective of whether they were pre- or post- menopausal). 
* Fisher’s exact test 







Table 6: Prevalence of disease features in simple heterozygotes and HFE wild-types by sex. 
  Men  p# Women  p# 
MCP 2/31 C282Y Simple 
Heterozygote 
11/94(12%) 0.43 8/103(8%) 0.38 
 H63D Simple 
Heterozygote 
7/41(17%) 0.81 9/55(16%) 0.32 
 HFE Wild-type 18/116(16%)  16/144(11%)  
Arthritis medicine2 C282Y Simple 
Heterozygote 
4/161(2%) *0.72 10/176(6%) 0.46 
 H63D Simple 
Heterozygote 
2/54(4%) *0.6 9/76(12%) 0.27 
 HFE Wild-type 3/164(2%)  15/197(8%)  
Fatigue3 C282Y Simple 
Heterozygote 
9/115(8%) 0.47 25/139(18%) 0.86 
 H63D Simple 
Heterozygote 
7/46(15%) 0.38 11/70(16%) 0.57 
 HFE Wild-type 15/144(10%)  33/176(19%)  
Raised AST/ALT4 C282Y Simple 
Heterozygote 
5/107(5%) 0.02 9/127(7%) *0.11 
 H63D Simple 
Heterozygote 
4/46(9%) 0.38 0/66(0%) *0.33 
 HFE Wild-type 19/139(14%)  5/169(3%)  
Liver disease5 C282Y Simple 
Heterozygote 
3/116(3%) *1.00 13/140(9%) 0.23 
 H63D Simple 
Heterozygote 
4/46(9%) *0.1 5/69(7%) 0.65 
 HFE Wild-type 4/142(3%)  10/175(6%)  
Hepatomegaly6 C282Y Simple 
Heterozygote 
3/91(3%) *0.73 1/98(1%) *0.64 
 H63D Simple 
Heterozygote 
0/41(0%) *0.32 2/54(4%) *0.63 
 HFE Wild-type 5/113(4%)  3/135(2%)  
* Fisher’s exact test 
1Presence of bony spur, tenderness or effusion of the 2nd and 3rd MCP joints on either hand.  Examination conducted by physicians 
blinded to genotype and HH status. 
2 Self reported answer to the questions “Has a doctor ever told you that you have arthritis or rheumatism?” followed by “If you have arthritis 
or rheumatism, do you take aspirin?” 
3Self reported answer to the question “Have you ever sought medical attention because of fatigue?” 
4Aspartate aminotransferase > 45 IU/L or alanine aminotransferase >40 IU/L 
5 Self reported answer to the question “Has a doctor ever told you that you have liver disease?” 
6 Liver enlargement defined as a liver span of 13cm or more.  Examination conducted by physicians blinded to genotype and HH status. 
















Table 7: Prevalence of disease in male simple heterozygotes with elevated iron indices compared with 
those with non-elevated iron indices. 
 Men Women 
 Elevated SF† Normal SF *p# Elevated SF† Normal SF *p# 
C282Y Simple Heterozygotes 
MCP 2/3 5/37(14%) 4/48(8%) 0.49 1/9(11%) 5/76(7%) 0.5 
Arthritis medicine 0/48(0%) 3/56(5%) 0.25 1/12(8%) 6/95(6%) 0.58 
Fatigue 6/43(14%) 3/54(6%) 0.18 2/12(17%) 12/94(13%) 0.66 
Raised AST/ALT 2/41(5%) 3/56(5%) 1.00 2/11(18%) 5/95(5%) 0.15 
Liver disease 1/43(2%) 0/55(0%) 0.44 1/12(8%) 12/94(13%) 1.00 
Hepatomegaly 0/34(0%) 3/48(6%) 0.26 0/8(0%) 0/74(0%) - 
H63D Simple Heterozygotes 
MCP 2/3 2/13(15%) 4/20(20%) 1.00 2/6(33%) 5/39(13%) 0.23 
Arthritis medicine 2/15(13%) ./22(.%) 0.16 2/10(20%) 5/46(11%) 0.6 
Fatigue 1/14(7%) 4/22(18%) 0.63 1/10(10%) 6/44(14%) 1.00 
Raised AST/ALT 1/14(7%) 2/22(9%) 1.00 0/10(0%) 0/46(0%) - 
Liver disease 2/14(14%) 1/22(5%) 0.55 0/10(0%) 3/43(7%) 1.00 
Hepatomegaly 0/13(.%) 0/20(.%) - 0/6(0%) 1/38(3%) 1.00 
† 6 male C282Y simple heterozygotes had elevated SF and elevated TS at either baseline or follow-up. 
* Fisher’s exact test 






Table 8: Prevalence of iron-overload-related disease in HFE simple heterozygotes. 



















0 0 0 0 0 0 
Provisional iron 
overload2 
0 2 2 0 1 1 
No iron overload3 16 99 115 16 117 133 
Total 16 101 117 16 118 134 






0 0 0 0 0 0 
Provisional iron 
overload2 
0 1 1 0 0 0 
No iron overload3 9 37 46 9 65 74 
Total 9 38 47 9 65 74 
Iron overload is categorized as one of the following 
1. Documented iron overload: Increased iron content shown by hepatic iron staining 3 or 4, iron concentration >90 µmol/g, 
or HII >1.9 (Whitlock14) or SF >1000 µg/L at baseline with documented therapeutic venesection. 
2. Provisional iron overload: Raised SF (>300 µg/L for males and post-menopausal women, >200 µg/L pre-menopausal 
women) in association with raised TS (>55% males, >45% females). 
3. No evidence of iron overload: Normal SF or elevated SF but in the context of normal TS during study period. 
 
Iron overload-related disease is defined as occurrence of at least one of the following five conditions in the context of 
documented iron overload as defined above: 
1. Hepatocellular carcinoma. 
2. Cirrhosis or fibrosis on percutaneous liver biopsy. 
3. Bony, tenderness or effusion of both of the second and third metacarpophalangeal joints on examination by study 
physician blinded to genotype. 
4. Raised serum aspartate aminotransferase (AST >45 IU/L) or serum alanine, aminotransferase (ALT >40 IU/L). 
5. Physician diagnosis due to presentation with HH-associated symptoms. 
 
Documented iron overload-related disease was considered present if participants had BOTH documented iron overload 
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